Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 4/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20124470 | 0.91 | PIM1 (0.38) | NOS3NOS2SYKPIM1IDH2 | |
| SCHEMBL25894645 | 0.83 | SYK (0.39) | NOS3NOS2SYKPIM1IDH2 | |
| SCHEMBL9938726 | 0.82 | SYK (0.40) | NOS3NOS2SYKIDH2MAP3K12 | |
| SCHEMBL9972431 | 0.81 | KARS1 (0.45) | NOS3NOS2SYKPIM1KARS1 | |
| SCHEMBL22135115 | 0.79 | SYK (0.39) | SYKPIM1IDH2KARS1MAP3K12 | |
| SCHEMBL1702136 | 0.79 | KARS1 (0.43) | NOS3NOS2SYKIDH2KARS1 | |
| SCHEMBL17434789 | 0.78 | IDH2 (0.44) | SYKIDH2KARS1MAP3K12AURKA | |
| SCHEMBL29498282 | 0.78 | IDH2 (0.44) | SYKIDH2KARS1MAP3K12AURKA | |
| SCHEMBL9942448 | 0.77 | LMNA (0.41) | SYKIDH2MAP3K12SLC40A1ALDH1A1 | |
| SCHEMBL22162991 | 0.76 | SYK (0.36) | SYKPIM1IDH2MAP3K12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-11649210-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-11649210-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-11649211-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-11649211-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2023-05-16 | — | — | US | disclosed |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2022-01-27 | — | — | US | disclosed |
| EP-3261642-B1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| WO-2016135055-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF VIRAL INFECTION | ABIVAX (FR) | 2016-09-01 | — | — | WO | disclosed |
| EP-3058940-A1 | Quinoline derivatives for use in the treatment or prevention of viral infection | ABIVAX (FR) | 2016-08-24 | — | — | EP | disclosed |
| EP-3058940-A1 | Quinoline derivatives for use in the treatment or prevention of viral infection | ABIVAX (FR) | 2016-08-24 | — | — | EP | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080953-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2012-06-21 | — | — | WO | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | NOS3 30/4885NOS2 130/4885SYK 1956/4885 |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR1H3, NR1H2, NR1H4 | NOS3 25/4885NOS2 105/4885SYK 1176/4885 |
| US-11649210-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | NR1H4, NR1I3, NR1H3 | NOS3 32/4885NOS2 56/4885SYK 2468/4885 |
| US-11649211-B2 | Use of quinoline derivatives for the treatment of inflammatory diseases | NR1H4, NR1I3, NR1H3 | NOS3 32/4885NOS2 56/4885SYK 2468/4885 |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | HAVCR2, CXCL8, IL36G | NOS3 2445/4885NOS2 2303/4885SYK 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.